tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

SanBio Co. Announces International Offering to Fund Key Clinical Trials

Story Highlights
SanBio Co. Announces International Offering to Fund Key Clinical Trials

Meet Your ETF AI Analyst

SanBio Co ( (JP:4592) ) has issued an update.

SanBio Co., Ltd. has announced the determination of issue price and other details for its new shares through an international offering, aiming to raise approximately 14,202 million yen. The funds will be used primarily for clinical trials and infrastructure development for its AKUUGO® and SB623 programs, enhancing its market position in Japan and the U.S.

The most recent analyst rating on (JP:4592) stock is a Sell with a Yen1010.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.

More about SanBio Co

SanBio Co., Ltd. operates in the biotechnology industry, focusing on the development and commercialization of regenerative cell medicines. The company is known for its innovative therapies targeting neurological conditions, with a market focus on Japan and the United States.

Average Trading Volume: 2,779,301

Technical Sentiment Signal: Strong Buy

Current Market Cap: Yen204.9B

Find detailed analytics on 4592 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1